Jove
Visualize
Contact Us

Related Experiment Videos

Targeting Kupffer cells with antisense oligonucleotides.

Biddanda C Ponnappa1, Yedy Israel

  • 1Department of Pathology, Anatomy and Cell Biology and Alcohol Research Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. Biddanda.Ponnappa@mail.tju.edu

Frontiers in Bioscience : a Journal and Virtual Library
|May 7, 2002
PubMed
Summary

Antisense oligonucleotides (ASOs) offer potential for treating liver injury by targeting Kupffer cells. However, effective in vivo delivery to these cells remains a challenge, with pH-sensitive liposomes showing promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut Microbiota-Derived Extracellular Vesicles Influence Alcohol Intake Preferences in Rats.

Journal of extracellular vesicles·2025
Same author

Intragastric administration of short chain fatty acids greatly reduces voluntary ethanol intake in rats.

Scientific reports·2024
Same author

Morphine self-administration is inhibited by the antioxidant N-acetylcysteine and the anti-inflammatory ibudilast; an effect enhanced by their co-administration.

PloS one·2024
Same author

Chronic Voluntary Morphine Intake Is Associated with Changes in Brain Structures Involved in Drug Dependence in a Rat Model of Polydrug Use.

International journal of molecular sciences·2023
Same author

Amelioration of morphine withdrawal syndrome by systemic and intranasal administration of mesenchymal stem cell-derived secretome in preclinical models of morphine dependence.

CNS neuroscience & therapeutics·2023
Same author

Role of Metabolism on Alcohol Preference, Addiction, and Treatment.

Current topics in behavioral neurosciences·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Hepatology
  • Immunology
  • Drug Delivery Systems

Background:

  • Proinflammatory reactions cause liver injury by releasing cytokines and prostanoids, primarily from Kupffer cells.
  • Kupffer cell ablation prevents liver damage, highlighting their critical role in disease pathogenesis.
  • Current therapies targeting cytokines, like anti-tumor necrosis factor-alpha (TNF-alpha) antibodies, show promise but face challenges.

Purpose of the Study:

  • To explore antisense oligonucleotides (ASOs) as a therapeutic strategy against Kupffer cell-mediated liver inflammation.
  • To address the challenges in designing and delivering ASOs effectively to target Kupffer cells in vivo.
  • To evaluate novel delivery systems for enhancing ASO efficacy in targeting Kupffer cells.

Main Methods:

  • Investigated antisense oligonucleotides (ASOs) targeting specific mRNAs to control inflammatory peptide production.

Related Experiment Videos

  • Utilized computer-aided configurational analysis to design effective ASOs with viable motifs (GGGA).
  • Evaluated anionic liposomes, lactosylated low-density lipoproteins (LDL), and pH-sensitive liposomes for in vivo ASO delivery to Kupffer cells.

    • Main Results:

    • ASOs demonstrate potential for gene expression modulation in controlling inflammatory responses.
    • Challenges in ASO design, in vivo delivery, and cellular uptake persist.
    • pH-sensitive liposomes and LDL-based systems show promise for targeted delivery of ASOs to Kupffer cells.

    Conclusions:

    • ASOs represent a novel therapeutic class for targeting Kupffer cell-derived pro-inflammatory mediators.
    • Effective in vivo delivery of ASOs to Kupffer cells remains a significant hurdle.
    • pH-sensitive liposomes and LDL offer promising strategies for targeted Kupffer cell delivery of ASOs.